Virtual reality could help young cancer survivors navigate life after treatment

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Any person assigned male at birth who is diagnosed with stage I-III TC (germ cell tumour of the testicles). 2. Aged between 15 and 39 years at the time of study inclusion. 3. Completed curative treatment comprising of at least one standard treatment modality (surgery, chemotherapy and/or radiotherapy) for treatment of their cancer. A maximum of 9 months from the end of curative treatment will be allowed. 4. Permitted treatment modalities: * Localised disease: orchiectomy with or without chemotherapy and/or radiotherapy. * Metastatic disease: orchiectomy and chemotherapy or radiotherapy or retroperitoneal surgery, or a combination of aforementioned treatments. First-line treatment only allowed. 5. Willing and able to provide a valid and signed informed consent and/or assent, as appropriate. 6. ECOG performance status 0-2. 7. Patients accept to use personal smartphone 8. Patients able to read and understand the local language Exclusion Criteria: 1. Non-testicular germ cell tumours (e.g., mediastinal primary or retroperitoneal primary tumours). 2. Non-germ cell TC. 3. Previous chemotherapy, radiotherapy, or surgery for TC other than that allowed in IC 4. 4. History of contralateral TC. 5. Any illness that would prevent the AYA TC survivor from giving a valid and signed informed consent, as assessed by the investigator. 6. Any illness that might be exacerbated by the use of an XR digital tool, as assessed by the investigator, including history of severe motion sickness, brain lesions and epilepsy. 7. Uncontrolled medical condition such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease (including but not limited to grade 2 or higher cardiac failure, arrythmia, unstable angina, history of myocardial infract in the 6 months which, in the opinion of the treating physician, would influence the assessment of long-term side effect of TC treatment. 8. AYA TC survivors with a "currently active" second malignancy other than non-melanoma skin cancers, superficial non-invasive (pTa or pTis) TCC of the bladder, or intratubular germ cell neoplasia. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years. 9. Chemotherapy or radiotherapy for malignant disease other than TC within the past 3 years.